Skip to main content
. 2018 Jan 24;56(2):e01093-17. doi: 10.1128/JCM.01093-17

FIG 2.

FIG 2

(A) The first and second dotted lines represent the susceptibility and intermediate breakpoints for ceftolozane-tazobactam, respectively. Shaded boxes identify results classified as minor errors. (B) The first and second dotted lines represent the susceptibility and intermediate breakpoints for ceftolozane-tazobactam, respectively. Shaded boxes identify results classified as minor errors.